{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:26:56Z","timestamp":1790803616096,"version":"4.1.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,6,10]],"date-time":"2027-06-10T00:00:00Z","timestamp":1812585600000},"content-version":"am","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-19-1-0517"],"award-info":[{"award-number":["W81XWH-19-1-0517"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.molmed.2025.10.008","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T06:43:23Z","timestamp":1763621003000},"page":"536-546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Emerging innovative treatments for leptomeningeal metastatic tumors"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0427-4426","authenticated-orcid":false,"given":"Nobuhiko","family":"Kanaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5474-0974","authenticated-orcid":false,"given":"Khalid","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2025.10.008_bb0005","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41571-024-00970-3","article-title":"Leptomeningeal metastatic disease: new frontiers and future directions","volume":"22","author":"Ozair","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.molmed.2025.10.008_bb0010","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4274\/ejbh.galenos.2021.2021-4-10","article-title":"Assessment of leptomeningeal carcinomatosis diagnosis, management and outcomes in patients with solid tumors over a decade of experience","volume":"17","author":"Rinehardt","year":"2021","journal-title":"Eur. J. Breast Health"},{"key":"10.1016\/j.molmed.2025.10.008_bb0015","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11060-025-05059-0","article-title":"Retrospective study of leptomeningeal metastasis: unveiling the indolent and rapid progression phases","volume":"174","author":"Xie","year":"2025","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.molmed.2025.10.008_bb0020","first-page":"v86","article-title":"Advances in the diagnosis, evaluation, and management of leptomeningeal disease","volume":"3","author":"Sener","year":"2021","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.molmed.2025.10.008_bb0025","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/jrr\/rrae059","article-title":"Craniospinal irradiation for leptomeningeal metastasis of solid tumors: survival analysis and prognostic factors","volume":"65","author":"Takeda","year":"2024","journal-title":"J. Radiat. Res."},{"key":"10.1016\/j.molmed.2025.10.008_bb0030","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1186\/s12885-020-06984-1","article-title":"Craniospinal irradiation(CSI) in patients with leptomeningeal metastases: risk-benefit-profile and development of a prognostic score for decision making in the palliative setting","volume":"20","author":"Devecka","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.molmed.2025.10.008_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411443","article-title":"Leptomeningeal metastases in melanoma patients: an update on and future perspectives for diagnosis and treatment","volume":"24","author":"Steininger","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2025.10.008_bb0040","doi-asserted-by":"crossref","first-page":"825","DOI":"10.14740\/wjon1910","article-title":"Simultaneous determination of methotrexate concentrations in human plasma and cerebrospinal fluid using two-dimensional liquid chromatography: applications in primary central nervous system lymphoma","volume":"15","author":"Wang","year":"2024","journal-title":"World. J. Oncol."},{"key":"10.1016\/j.molmed.2025.10.008_bb0045","first-page":"513","article-title":"Temozolomide: an updated overview of resistance mechanisms, nanotechnology advances and clinical applications","volume":"19","author":"Ortiz","year":"2021","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.molmed.2025.10.008_bb0050","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11060-012-0879-3","article-title":"Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors","volume":"109","author":"Segura","year":"2012","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.molmed.2025.10.008_bb0055","doi-asserted-by":"crossref","first-page":"54","DOI":"10.14791\/btrt.2018.6.e12","article-title":"A retrospective analysis of the clinical outcomes of leptomeningeal metastasis in patients with solid tumors","volume":"6","author":"Kim","year":"2018","journal-title":"Brain Tumor Res. Treat."},{"key":"10.1016\/j.molmed.2025.10.008_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101832","article-title":"Therapeutic role of EGFR \u2013 tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis","volume":"39","author":"Jia","year":"2024","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.molmed.2025.10.008_bb0065","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/S1470-2045(17)30689-7","article-title":"Leptomeningeal metastases in non-small-cell lung cancer","volume":"19","author":"Cheng","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2025.10.008_bb0070","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1158\/2159-8290.CD-24-0024","article-title":"A next-generation BRAF inhibitor overcomes resistance to BRAF inhibition in patients with BRAF-mutant cancers using pharmacokinetics-informed dose escalation","volume":"14","author":"Yaeger","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molmed.2025.10.008_bb0075","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1470-2045(24)00735-6","article-title":"Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study","volume":"26","author":"Long","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2025.10.008_bb0080","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood\u2013brain barrier: structure, regulation and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.molmed.2025.10.008_bb0085","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.trecan.2021.02.003","article-title":"Next-generation immunotherapies for brain metastatic cancers","volume":"7","author":"L\u00f3pez V\u00e1zquez","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.molmed.2025.10.008_bb0090","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/annonc\/mdw134","article-title":"Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma","volume":"27","author":"Geukes Foppen","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molmed.2025.10.008_bb0095","first-page":"423","article-title":"Advances in targeted therapy for brain metastases in human epidermal growth factor receptor 2 (HER2)-positive breast cancer: a focus on ADCs and TKIs","volume":"17","author":"Rao","year":"2025","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"10.1016\/j.molmed.2025.10.008_bb0100","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cllc.2012.06.004","article-title":"Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma","volume":"14","author":"Zhao","year":"2013","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.molmed.2025.10.008_bb0105","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1158\/1078-0432.CCR-12-0357","article-title":"The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations","volume":"18","author":"Heon","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2025.10.008_bb0110","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s13691-015-0231-9","article-title":"Marked improvement in leptomeningeal carcinomatosis and spinal cord metastases following alectinib treatment of crizotinib-resistant, ALK-positive lung adenocarcinoma","volume":"5","author":"Kuribayashi","year":"2016","journal-title":"Int. Cancer Conf. J."},{"key":"10.1016\/j.molmed.2025.10.008_bb0115","first-page":"10","article-title":"T790M and acquired resistance of EGFR TKI: a literature review of clinical reports","volume":"3","author":"Ma","year":"2011","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.molmed.2025.10.008_bb0120","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.molmed.2025.10.008_bb0125","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study","volume":"38","author":"Yang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2025.10.008_bb0130","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1200\/JCO.2016.70.5749","article-title":"Three-year follow-up of an alectinib phase I\/II study in ALK-positive non-small-cell lung cancer: AF-001JP","volume":"35","author":"Tamura","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2025.10.008_bb0135","doi-asserted-by":"crossref","first-page":"379","DOI":"10.21037\/tlcr-22-638","article-title":"Targeting lung cancer brain metastases: a narrative review of emerging insights for anaplastic lymphoma kinase (ALK)-positive disease","volume":"12","author":"Nelson","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.molmed.2025.10.008_bb0140","article-title":"Long-term efficacy and safety of lorlatinib in Japanese patients with ALK-positive advanced NSCLC-a brief report from the CROWN study","volume":"5","author":"Teraoka","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.molmed.2025.10.008_bb0145","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaoncol.2022.5610","article-title":"Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial","volume":"9","author":"Lin","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.molmed.2025.10.008_bb0150","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2112491119","article-title":"Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer","volume":"119","author":"Cordero","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2025.10.008_bb0155","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ade8732","article-title":"Gene-edited and -engineered stem cell platform drives immunotherapy for brain metastatic melanomas","volume":"15","author":"Kanaya","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2025.10.008_bb0160","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1158\/1078-0432.CCR-21-1694","article-title":"Single-cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases","volume":"27","author":"Smalley","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2025.10.008_bb0165","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/jnci\/djaf006","article-title":"Engineered allogeneic stem cells orchestrate T lymphocyte driven immunotherapy in immunosuppressive leptomeningeal brain metastasis","volume":"117","author":"Kanaya","year":"2025","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.molmed.2025.10.008_bb0170","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1038\/s43018-024-00858-2","article-title":"Dura immunity configures leptomeningeal metastasis immunosuppression for cerebrospinal fluid barrier invasion","volume":"5","author":"Zhao","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.molmed.2025.10.008_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104539","article-title":"A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases","volume":"90","author":"Raeber","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.molmed.2025.10.008_bb0180","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41573-018-0011-2","article-title":"Interferons \u03b1 and \u03b2 in cancer: therapeutic opportunities from new insights","volume":"18","author":"Borden","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molmed.2025.10.008_bb0185","first-page":"1123","volume":"52","author":"List","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2025.10.008_bb0190","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000283","article-title":"Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2","volume":"3","author":"Glitza","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.molmed.2025.10.008_bb0195","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2025.10.008_bb0200","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.10.008_bb0205","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejca.2021.03.037","article-title":"Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments","volume":"150","author":"Zheng","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.molmed.2025.10.008_bb0210","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.1038\/s41467-021-25859-y","article-title":"Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis","volume":"12","author":"Brastianos","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2025.10.008_bb0215","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.1038\/s41467-021-25860-5","article-title":"Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases","volume":"12","author":"Prakadan","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2025.10.008_bb0220","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/neuonc\/noaf025","article-title":"Intrathecal sintilimab for leptomeningeal metastases of non-small cell lung cancer failed from targeted therapy and intrathecal chemotherapy (LMIS study)","volume":"27","author":"Fan","year":"2025","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.molmed.2025.10.008_bb0225","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s11060-024-04843-8","article-title":"Intrathecal anti-PD-1 treatment in metastatic melanoma patients with leptomeningeal disease (LMD): real-world data and evidence","volume":"170","author":"Zhen","year":"2024","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.molmed.2025.10.008_bb0230","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41591-022-02170-x","article-title":"Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results","volume":"29","author":"Glitza Oliva","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2025.10.008_bb0235","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/s41586-025-09012-z","article-title":"Interferon-\u03b3 orchestrates leptomeningeal anti-tumour response","volume":"643","author":"Remsik","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2025.10.008_bb0240","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/s41417-023-00588-0","article-title":"Oncolytic HSV1 targets different growth phases of breast cancer leptomeningeal metastases","volume":"30","author":"Kuruppu","year":"2023","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.molmed.2025.10.008_bb0245","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-17-2041","article-title":"Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2(+) breast cancer metastasis to the brain","volume":"24","author":"Priceman","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2025.10.008_bb0250","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","article-title":"Intravenous and intracranial GD2-CAR T cells for H3K27M(+) diffuse midline gliomas","volume":"637","author":"Monje","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2025.10.008_bb0255","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-53220-6","article-title":"PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial","volume":"15","author":"Stein","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2025.10.008_bb0260","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1186\/s12967-025-06608-x","article-title":"Efficacy and safety of third-generation CD19-CAR T cells incorporating CD28 and TLR2 intracellular domains for B-cell malignancies with central nervous system involvement: results of a pivotal trial","volume":"23","author":"He","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.molmed.2025.10.008_bb0265","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2408771","article-title":"Enhanced CAR T-Cell therapy for lymphoma after previous failure","volume":"392","author":"Svoboda","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.10.008_bb0270","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2025.10.008_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104513","article-title":"A comprehensive review of current treatment modalities for leptomeningeal carcinomatosis in breast cancer","volume":"204","author":"Morris","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.molmed.2025.10.008_bb0280","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2025.10.008_bb0285","article-title":"Immune response recalibration using immune therapy and biomimetic nano-therapy against high-grade gliomas and brain metastases","volume":"20","author":"Sandhbor","year":"2025","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.molmed.2025.10.008_bb0290","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.molmed.2025.10.008_bb0295","article-title":"Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13R\u03b12 are effective against heterogeneous glioblastoma","volume":"5","author":"Schmidts","year":"2023","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.molmed.2025.10.008_bb0300","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.molmed.2025.10.008_bb0305","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2025.10.008_bb0310","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41375-024-02444-y","article-title":"Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy","volume":"38","author":"Lei","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.molmed.2025.10.008_bb0315","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/MPH.0b013e3181914709","article-title":"Delayed recognition of intrathecal methotrexate overdose","volume":"31","author":"Malbora","year":"2009","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.molmed.2025.10.008_bb0320","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/jjco\/hyab155","article-title":"Clinical efficacy and safety of different doses of intrathecal methotrexate in the treatment of leptomeningeal carcinomatosis: a prospective and single-arm study","volume":"51","author":"Hou","year":"2021","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2025.10.008_bb0325","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11060-022-04118-0","article-title":"Intrathecal therapy for the management of leptomeningeal metastatic disease: a scoping review of the current literature and ongoing clinical trials","volume":"160","author":"Palmisciano","year":"2022","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.molmed.2025.10.008_bb0330","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s10637-011-9632-6","article-title":"Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis: efficacy and long-term safety in a single institution","volume":"30","author":"Brion","year":"2012","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.molmed.2025.10.008_bb0335","first-page":"3394","article-title":"A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors","volume":"5","author":"Glantz","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2025.10.008_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125202","article-title":"Navigating translational research in nanomedicine: A strategic guide to formulation and manufacturing","volume":"671","author":"Zhang","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.molmed.2025.10.008_bb0345","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3390\/cancers15030685","article-title":"The evolving landscape of leptomeningeal cancer from solid tumors: a systematic review of clinical trials","volume":"15","author":"Marenco-Hillembrand","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.molmed.2025.10.008_bb0350","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.addr.2020.02.006","article-title":"Intrathecal drug delivery in the era of nanomedicine","volume":"165-166","author":"Fowler","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.molmed.2025.10.008_bb0355","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/neuonc\/noac195","article-title":"A phase I\/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: safety, efficacy, and cerebrospinal fluid pharmacokinetics","volume":"25","author":"Kumthekar","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.molmed.2025.10.008_bb0360","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2018.02.032","article-title":"Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis","volume":"95","author":"Bonneau","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.molmed.2025.10.008_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102046","article-title":"Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: a metanalysis with meta-regression","volume":"88","author":"Zagouri","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.molmed.2025.10.008_bb0370","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1158\/0008-5472.CAN-18-0363","article-title":"Intrathecal viral vector delivery of trastuzumab prevents or inhibits tumor growth of human HER2-positive xenografts in mice","volume":"78","author":"Rothwell","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2025.10.008_bb0375","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41417-018-0060-z","article-title":"A model of breast cancer meningeal metastases: characterization with in vivo molecular imaging","volume":"26","author":"Kuruppu","year":"2019","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.molmed.2025.10.008_bb0380","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/s12885-023-10806-5","article-title":"Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study","volume":"23","author":"Zhou","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.molmed.2025.10.008_bb0385","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe8671","article-title":"Anti-EGFR VHH-armed death receptor ligand-engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers","volume":"7","author":"Kitamura","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.molmed.2025.10.008_bb0390","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/stcltm\/szad033","article-title":"Fate and efficacy of engineered allogeneic stem cells targeting cell death and proliferation pathways in primary and brain metastatic lung cancer","volume":"12","author":"Moleirinho","year":"2023","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.molmed.2025.10.008_bb0395","doi-asserted-by":"crossref","first-page":"73312","DOI":"10.18632\/oncotarget.20272","article-title":"Leptomeningeal disease: current diagnostic and therapeutic strategies","volume":"8","author":"Nayar","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.molmed.2025.10.008_bb0400","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/s41588-025-02167-5","article-title":"The multilayered transcriptional architecture of glioblastoma ecosystems","volume":"57","author":"Nomura","year":"2025","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2025.10.008_bb0405","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41417-024-00740-4","article-title":"Single-cell atlas reveals the immunosuppressive microenvironment and Treg cells landscapes in recurrent Glioblastoma","volume":"31","author":"Wang","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.molmed.2025.10.008_bb0410","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.21037\/tlcr-2025-163","article-title":"Advances in the research of leptomeningeal metastases in non-small cell lung cancer: a narrative review","volume":"14","author":"Hong","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.molmed.2025.10.008_bb0415","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/02648725.2023.2191069","article-title":"Cerebrospinal fluid exosomal microRNAs as biomarkers for diagnosing or monitoring the progression of non-small cell lung cancer with leptomeningeal metastases","volume":"40","author":"Li","year":"2024","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"10.1016\/j.molmed.2025.10.008_bb0420","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1126\/science.aaz2193","article-title":"Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.molmed.2025.10.008_bb0425","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41421-025-00828-7","article-title":"Immunological and pathological characteristics of brain parenchymal and leptomeningeal metastases from non-small cell lung cancer","volume":"11","author":"Zhou","year":"2025","journal-title":"Cell Discov."},{"key":"10.1016\/j.molmed.2025.10.008_bb0430","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2024.2375521","article-title":"Drug delivery in leptomeningeal disease: navigating barriers and beyond","volume":"31","author":"Arshad","year":"2024","journal-title":"Drug Deliv."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147149142500259X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147149142500259X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T08:04:50Z","timestamp":1781165090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147149142500259X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":86,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S147149142500259X"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2025.10.008","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging innovative treatments for leptomeningeal metastatic tumors","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2025.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}